Galan: Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection

Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection

Galan et al., Pathogens and Global Health, doi:10.1080/20477724.2021.1890887

Galan et al., Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe.., Pathogens and Global Health, doi:10.1080/20477724.2021.1890887

Mar 2021 Source PDF

Twitter
Facebook

All Studies Meta

RCT 168 very late stage severe condition hospitalized patients comparing CQ, HCQ, and ivermectin not showing significant differences. Authors were unable to add a control arm due to ethical issues.

Authors claim that "the mortality rates of the three groups are very similar to historical reports of other studies that used placebo in hospitalized patients", without providing any reference. However [sciencedirect.com] shows 43% hospital mortality in the northern region of Brazil, where the study was performed, from which we can estimate the mortality with ivermectin in this study is 47% lower, RR 0.53. Further, the study is restricted to more severe cases, hence the expected mortality may be higher.

1. sciencedirect.com, https://www.sciencedirect.com/science/article/pii/S2214109X20302850.

Important missing comments or errors? Let us know.

Galan et al., 8 Mar 2021, peer-reviewed, 19 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ivermectin All

Abstract: Pathogens and Global Health ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ypgh20 Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection Luis Enrique Bermejo Galan, Nayara Melo dos Santos, Mauro Shosuka Asato, Jucineide Vieira Araújo, Adriana de Lima Moreira, Aléxia Mahara Marques Araújo, Artur Diogenes Pinheiro Paiva, Diego Guilherme Santos Portella, Frank Silas Saldanha Marques, Gabriel Melo Alexandre Silva, Joana de Sousa Resende, Marycassiely Rodrigues Tizolim, Poliana Lucenados Santos, Steffi Ferreira Buttenbender, Stephanye Batista de Andrade, Roberto Carlos Cruz Carbonell, Juliana Gomes Da Rocha, Ruy Guilherme Silveira de Souza & Allex Jardim da Fonseca To cite this article: Luis Enrique Bermejo Galan, Nayara Melo dos Santos, Mauro Shosuka Asato, Jucineide Vieira Araújo, Adriana de Lima Moreira, Aléxia Mahara Marques Araújo, Artur Diogenes Pinheiro Paiva, Diego Guilherme Santos Portella, Frank Silas Saldanha Marques, Gabriel Melo Alexandre Silva, Joana de Sousa Resende, Marycassiely Rodrigues Tizolim, Poliana Lucenados Santos, Steffi Ferreira Buttenbender, Stephanye Batista de Andrade, Roberto Carlos Cruz Carbonell, Juliana Gomes Da Rocha, Ruy Guilherme Silveira de Souza & Allex Jardim da Fonseca (2021) Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection, Pathogens and Global Health, 115:4, 235-242, DOI: 10.1080/20477724.2021.1890887 To link to this article: https://doi.org/10.1080/20477724.2021.1890887 Published online: 08 Mar 2021. Submit your article to this journal Article views: 14709 View related articles View Crossmark data Citing articles: 1 View citing articles Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ypgh20 PATHOGENS AND GLOBAL HEALTH 2021, VOL. 115, NO. 4, 235–242 https://doi.org/10.1080/20477724.2021.1890887 ARTICLE Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection Luis Enrique Bermejo Galan a,b, Nayara Melo dos Santos a, Mauro Shosuka Asato a, Jucineide Vieira Araújo a,b, Adriana de Lima Moreira b, Aléxia Mahara Marques Araújo b, Artur Diogenes Pinheiro Paiva b, Diego Guilherme Santos Portella b, Frank Silas Saldanha Marques Gabriel Melo Alexandre Silva b, Joana de Sousa Resende b, Marycassiely Rodrigues Tizolim b, Poliana Lucenados Santos b, Steffi Ferreira Buttenbender b, Stephanye Batista de Andrade b, Roberto Carlos Cruz Carbonell a,b, Juliana Gomes Da Rocha c, Ruy Guilherme Silveira de Souza b and Allex Jardim da Fonseca a,b,c b , a Department of Infectious Diseases of Hospital Geral De Roraima. Universidade Federal De Roraima. Boa Vista Brazil; bPost Graduate Program in Health Science of Universidade Federal De Roraima, Health Science Center, Boa Vista, Brazil; cClinical Research Center of the Oncological Center of Roraima - Boa Vista - Brazil ABSTRACT KEYWORDS Objective: Given the urgent need for strategies to minimize the damage caused by this pandemic, this study performed a randomized, double-blind phase 2 study to assess the safety of the effectiveness of chloroquine (CQ), hydroxychloroquine (HCQ) or ivermectin in severe forms of COVID-19, in addition to identifying predictors of mortality in..

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit